journavx - Search News

New non-opioid painkiller Journavx approved by FDA

U.S. News & World Report · 1d

What to Know About Journavx, the Non-Opioid Pain Medication Just Approved by the FDA

The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in more than 20 years.

The Washington Post · 1d

FDA approves new, non-opioid painkiller Journavx

The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller to win FDA approval in more than 20 years.

Scientific American · 1d

What Is Journavx, the New Opioid-Free Painkiller from Vertex?

The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment

FDA approves nonopioid Journavx for moderate to severe acute pain

The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...

1d

Cautious Outlook on Vertex Pharmaceuticals Amid Journavx Approval and Pricing Concerns

Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence ...

11h

At $31 a day, is Vertex’s new non-addictive painkiller worth the price?

Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...

1d

What's Happening With VRTX Stock?

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results